RecruitingPHASE1, PHASE2NCT06532799

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Studying NON RARE IN EUROPE: Adenocarcinoma of stomach

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Essen Biotech
Intervention
Tumor Infiltrating Lymphocytes (TIL)(biological)
Enrollment
75 enrolled
Eligibility
16-90 years · All sexes
Timeline
20242026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06532799 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

← Back to all trials